[HTML][HTML] TP53 gain-of-function mutation is a poor prognostic factor in high-methylated metastatic colorectal cancer
S Wakayama, K Ouchi, S Takahashi, Y Yamada… - Clinical Colorectal …, 2023 - Elsevier
Background Neither TP53 mutation nor DNA methylation status has been established as a
biomarker alone of metastatic colorectal cancer. We analyzed the association between TP53 …
biomarker alone of metastatic colorectal cancer. We analyzed the association between TP53 …
[HTML][HTML] Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer …
K Ouchi, S Takahashi, K Sasaki, Y Yoshida… - International Journal of …, 2024 - Springer
Purpose The genome-wide DNA methylation status (GWMS) predicts of therapeutic
response to anti-epidermal growth factor receptor (EGFR) antibodies in treating metastatic …
response to anti-epidermal growth factor receptor (EGFR) antibodies in treating metastatic …
[HTML][HTML] Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of …
S Takahashi, K Ouchi, Y Sakamoto, T Mori… - Journal of …, 2023 - ncbi.nlm.nih.gov
Background Little is known about the biweekly combined use of cetuximab and
chemotherapy as second-line treatment of metastatic colorectal cancer (mCRC). Recently …
chemotherapy as second-line treatment of metastatic colorectal cancer (mCRC). Recently …